Journal article

Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist: Hip Ratio, Is Causal for Endometrial Cancer

Jodie N Painter, Tracy A O'Mara, Louise Marquart, Penelope M Webb, John Attia, Sarah E Medland, Timothy Cheng, Joe Dennis, Elizabeth G Holliday, Mark McEvoy, Rodney J Scott, Shahana Ahmed, Catherine S Healey, Mitul Shah, Maggie Gorman, Lynn Martin, Shirley V Hodgson, Matthias W Beckmann, Arif B Ekici, Peter A Fasching Show all

Cancer Epidemiology Biomarkers & Prevention | AMER ASSOC CANCER RESEARCH | Published : 2016


Awarded by NHMRC

Awarded by Cancer Research UK

Awarded by European Community

Awarded by NIH

Awarded by Post-Cancer GWAS initiative

Awarded by Department of Defence

Awarded by Cancer Council Queensland

Awarded by Cancer Council Tasmania

Awarded by Wellcome Trust

Awarded by Medical Research Council

Awarded by Wellcome Trust Centre for Human Genetics Core grant

Awarded by NCI of United States Public Health Service

Awarded by NCI of United States Public Health Service (GAME-ON the NCI Cancer Post-GWAS Initiative)

Awarded by Stockholm County Council

Awarded by Karolinska Institutet

Funding Acknowledgements

The iCOGS endometrial cancer analysis was supported by NHMRC project grant (ID#1031333; to A.B. Spurdle, D.F. Easton, and A.M. Dunning). A.B. Spurdle and P.M. Webb are supported by the NHMRC Fellowship scheme. IT is supported by Cancer Research UK and the Oxford Comprehensive Biomedical Research Centre. T. Cheng is supported by the Rhodes Trust and the Nuffield Department of Medicine. Funding for the iCOGS infrastructure came from the European Community's Seventh Framework Programme under grant agreement nr. 223175 (HEALTH-F2-2009-223175; COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, and C8197/A16565), the NIH (CA128978) and Post-Cancer GWAS initiative(1U19 CA148537, 1U19 CA148065, and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.ANECS recruitment was supported by project grants from the NHMRC (ID#339435), The Cancer Council Queensland (ID# 4196615), and Cancer Council Tasmania (ID# 403031 and ID# 457636). SEARCH recruitment was funded by a programme grant from Cancer Research UK (C490/A10124). Stage I and stage II case genotyping was supported by the NHMRC (ID# 552402, ID# 1031333). This study makes use of data generated by the Wellcome Trust Case-Control Consortium (WTCCC). A full list of the investigators who contributed to the generation of the data is available from for the project was provided by the Wellcome Trust under award 076113. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02; funding for this project was provided by the Wellcome Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA grant, Wellcome Trust Centre for Human Genetics Core grant 090532/Z/09Z, and CORGI was funded by Cancer Research UK. Recruitment of the QIMR Berghofer controls was supported by the NHMRC. The University of Newcastle, the Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family Foundation, the Hunter Medical Research Institute, and the Hunter Area Pathology Service all contributed toward the costs of establishing the Hunter Community Study.The Bavarian Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of the University of Erlangen. The Leuven Endometrium Study (LES) was supported by the Verelst Foundation for Endometrial Cancer. The Mayo Endometrial Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the NCI of United States Public Health Service (R01 CA122443, P30 CA15083, P50 CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19 CA148112), the Fred C and Katherine B Andersen Foundation, the Mayo Foundation, and the Ovarian Cancer Research Fund with support of the Smith family, in memory of Kathryn Sladek Smith. MoMaTEC received financial support from a Helse Vest Grant, the University of Bergen, Melzer Foundation, The Norwegian Cancer Society (Harald Andersens legat), The Research Council of Norway and Haukeland University Hospital. The Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the University of Newcastle, The NBN Children's Cancer Research Group, Jennie Thomas, and the Hunter Medical Research Institute. RENDOCAS was supported through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet (numbers: 20110222, 20110483, 20110141, and DF 07015], The Swedish Labor Market Insurance (number 100069) and The Swedish Cancer Society (number 11 0439). The Cancer Hormone Replacement Epidemiology in Sweden Study (CAHRES, formerly called The Singapore and Swedish Breast/Endometrial Cancer Study; SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the U.S. NIH, and the Susan G. Komen Breast Cancer Foundation.The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research UK (C1287/A10118, C1287/A12014). The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07), and the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. Additional funding for individual control groups is detailed in the Supplementary Information.